Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28191613 | 0.98 | GAA (0.66) | GAAKMT2AMEN1MAPK1SIGMAR1 | |
| SCHEMBL1600111 | 0.93 | KMT2A (0.65) | KMT2AMEN1MAPK1SIGMAR1KDM4E | |
| SCHEMBL18182316 | 0.86 | MAPK1 (0.72) | KMT2AMEN1MAPK1SIGMAR1KDM4E | |
| SCHEMBL26113758 | 0.86 | KMT2A (0.56) | KMT2AMEN1MAPK1SIGMAR1KDM4E | |
| SCHEMBL9397289 | 0.86 | CXCR4 (0.60) | KMT2AMEN1 | |
| SCHEMBL2094772 | 0.86 | KMT2A (0.50) | GAAKMT2AMEN1MAPK1SIGMAR1 | |
| SCHEMBL3377384 | 0.85 | KDM4E (0.64) | GAAKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL14924460 | 0.85 | GAA (0.62) | GAAKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL11296180 | 0.85 | ALDH1A1 (0.59) | GAAKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL1640898 | 0.85 | HTT (0.76) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103626713-B | Ketone (thioketones) the class compound of nitrogen (oxygen) heterocycle pentane 2, its pharmaceutical composition, preparation method and purposes | 中国科学院上海药物研究所 | 2017-07-04 | — | — | CN | disclosed |
| EP-2867219-B1 | ASYMMETRICAL REVERSIBLE NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION | UNIV CORNELL (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9156826-B2 | Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration | CORNELL UNIVERSITY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150191453-A1 | ASYMMETRICAL REVERSIBLE NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION | SOCIETAL CDMO, INC. | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191453-A1 | ASYMMETRICAL REVERSIBLE NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION | TNNC1, IMMT, MDH2 | GAA 4692/4885KMT2A 2363/4885MEN1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.